Monday, November 30, 2015 4:41:08 PM
EndoTarget, even more interesting.... is now we find out "Roy Buchanan" of Piper Jaffray exits and lands where ?? The same place as Debjit Chattopadhyay ==> Janney !
----------------
Mr. Buchanan covers the biotechnology space from the New York office. Prior to joining Janney, he was a senior associate for three years at Piper Jaffray, where he covered small-to-mid cap biotech companies. Prior to his role at Piper Jaffray, he covered the same space at JMP Securities for two years as an associate. Mr. Buchanan received his Ph.D. in biology from Columbia University in New York and his BS in chemical engineering from the Colorado School of Mines.
http://www.janney.com/institutions--corporations/equities/equity-research/our-team/roy-buchanan-ph-d
---------------
Janney Healthcare Analysts
Roy Buchanan, Ph.D.
Vice President, Biotechnology
212-940-6985
Debjit Chattopadhyay, Ph.D.
Managing Director, Biotechnology
215-665-6224
Paul Knight, CFA
Managing Director, Head of Healthcare Research
212-888-2696
Ken Trbovich, CFA
Director, Specialty Pharmaceuticals
215-665-6290
http://www.janney.com/institutions--corporations/equities/equity-research/our-team
---------------------
For those that want to verify Roy was on some CC's ..
CJ's posts below re: transcripts with Roy Buchanan ( showing up in place of Charles Duncan)
Sept 2014
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106136873&txt2find=roy|buchanan
Dec 2014
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106136873&txt2find=roy|buchanan
March 2015
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111728918&txt2find=roy|buchanan
------------
Why does Janney all of a sudden have interest in two additional healthcare analysts and both happen to cover Peregrine Pharmaceuticals ? Coincidence ....? I do not believe so and I'd even take it as far as Janney was targeting those close to Peregrine and maybe they figure they get some inside scoop of whats to come by picking up Roy and Debjit
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Recent CDMO News
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:33:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:32:11 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM